Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00317486
Registration number
NCT00317486
Ethics application status
Date submitted
21/04/2006
Date registered
25/04/2006
Date last updated
15/02/2010
Titles & IDs
Public title
Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
Query!
Scientific title
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
Query!
Secondary ID [1]
0
0
AC-052-405
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Cardiovascular
0
0
0
0
Query!
Hypertension
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - bosentan
Treatment: Drugs: bosentan
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change from baseline to Week 16 in oxygen saturation at rest with room air
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Primary outcome [2]
0
0
Change from baseline to Week 16 in indexed pulmonary vascular resistance
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Secondary outcome [1]
0
0
Changes from baseline to Week 16 in cardiac hemodynamics
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Eligibility
Key inclusion criteria
1. Male or female patients at least 12 years with a body weight at least 40 kg
(inclusive) and with a functional class III (1998 WHO classification).
2. Patients with pulmonary arterial hypertension related to Eisenmenger physiology
echocardiographically established as atrial septal defect at least 2 cm effective
diameter and/or ventricular septal defect at least 1 cm effective diameter; PAH
confirmed via cardiac catheterization: mean pulmonary arterial pressure >25 mm Hg,
pulmonary capillary wedge pressure <15 mm Hg and pulmonary vascular resistance >3 mm
Hg/l/min.
3. Patients with documented oxygen saturation up to 90%, and >70% (at rest, with room
air).
4. Patients able to perform a 6-minute walk test at least 150 m, and up to 450 m.
5. Patients stable for at least 3 months prior to screening.
6. Bosentan naïve patients.
7. Female patients who are surgically sterile, postmenopausal or have documented
infertility.
8. Female patients of childbearing potential using one of the following methods of
contraception: Barrier-type devices (e.g., condom, diaphragm) used ONLY in combination
with a spermicide. A double-barrier method is recommended; intrauterine devices
(IUDs); oral or implanted contraceptives, if used in combination with a barrier
method.
9. Patients providing written informed consent.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Pregnant patients, nursing mothers.
2. Patients with left ventricular dysfunction (ejection fraction <40%).
3. Patients with restrictive lung disease (TLC<70% predicted); obstructive lung disease
(FEV1<70% predicted, with FEV1/FVC<60%)
4. Patients with systolic blood pressure < 85 mm Hg.
5. Patients with other conditions that may affect the ability to perform a 6-minute walk
test.
6. Patients unable to provide informed consent and comply with the patient protocol.
7. Patients with known coronary arterial disease.
8. Patients with serum creatinine >125 µM/l.
9. Patients with iron deficiency (serum ferritin <10 ng/ml) unless corrected by iron
supplement.
10. Patients with hemoglobin or hematocrit that is more than 30% below the normal range
(patients with secondary polycythemia are permitted).
11. Patients with AST and/or ALT values greater than 3 times the upper limit of normal.
12. Patients who have started or stopped treatment for PAH within one month of screening,
excluding anticoagulation.
13. Patients who are receiving glyburide (glibenclamide), cyclosporine A or tacrolimus at
inclusion or are expected to receive any of these drugs during the study.
14. Patients who are receiving vasodilators including, but not limited to epoprostenol or
prostacyclin analogues, or are expected to receive any of these drugs during the
study.
15. Patients active on organ transplant lists.
16. Patients taking phosphodiesterase inhibitors or endothelin receptor antagonists (other
than bosentan) or any other investigational drugs/devices.
17. Patients with planned surgical intervention during the study period.
18. Cardiac catheterization-specific exclusion criteria:
1. Patients who cannot safely have catheterization performed as indicated.
2. Patients in whom shunting is not at the atrial or ventricular level.
3. Patients with nonequal pulmonary venous desaturation that theoretically cannot be
corrected with administration of 100% non-rebreather-supplied oxygen.
4. Patients with nonpulsatile pulmonary blood flow, or with multiple sources of
pulmonary blood flow.
5. Patients with discontinuous pulmonary arteries, peripheral pulmonary arterial or
venous stenosis > 25% size of native PA or creating unequal bilateral PA mean
pressures, PA band with gradient > 20 mm Hg, tetralogy of fallot/pulmonary
atresia, VSD/pulmonary atresia, DORV/pulmonary atresia, truncus arteriosus,
scimitar syndrome.
6. Patients where SVC sampling cannot be performed, or where SVC sampling may be
contaminated
7. Patients with ductus arteriosus.
8. Patients with mitral or pulmonary venous stenosis, intracavitary LV outflow
obstruction, sub, valvar or supravalvar aortic stenosis or aortic coarctation.
9. Patients with <10 indexed Wood units, greater than moderate mitral regurgitation,
mean pulmonary venous pressure > 16 mm Hg, pulmonary venous "v" waves > 20 mm Hg,
systemic ventricular end-diastolic pressure > 16 mm Hg; patients with recognized
extracardiac systemic venous collaterals to the pulmonary venous circulation,
patients with recognized hepatic wedge pressure-inferior vena cava pressure
gradient > 12 mm Hg.
10. Patients (during catheterization) with uncorrectable hypercarbia with pCO2 >55 mm
Hg; patients with uncorrectable acidemia with pH <7.34; patients in active pain
or distress; unconscious or mechanically ventilated patients; patients with
unstable systemic or pulmonary blood flow; systemic arterial or pulmonary artery
pressures or hematocrit (change of > 25% during catheterization); unstable
cardiac rhythm dissimilar to baseline cardiac rhythm during physical examination
assessments for the entire duration of the catheterization excepting nonsustained
arrhythmia; patients with documented or recognized air embolism, hemorrhage,
cardiac, cerebral or peripheral organ ischemia occurring during or immediately
preceding the catheterization.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2005
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
54
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital - Central Clinical School - Camperdown
Query!
Recruitment hospital [2]
0
0
The Royal Melbourne Hospital - Victoria
Query!
Recruitment postcode(s) [1]
0
0
NSW 2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
3050 - Victoria
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Massachusetts
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Texas
Query!
Country [3]
0
0
Austria
Query!
State/province [3]
0
0
Wien
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Leuven
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Alberta
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Ontario
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Paris
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Bad Oeynhausen
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Munchen
Query!
Country [10]
0
0
Italy
Query!
State/province [10]
0
0
Bologna
Query!
Country [11]
0
0
Italy
Query!
State/province [11]
0
0
Pavia
Query!
Country [12]
0
0
Netherlands
Query!
State/province [12]
0
0
Groningen
Query!
Country [13]
0
0
Spain
Query!
State/province [13]
0
0
Madrid
Query!
Country [14]
0
0
United Kingdom
Query!
State/province [14]
0
0
Glasgow
Query!
Country [15]
0
0
United Kingdom
Query!
State/province [15]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Actelion
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study evaluates the effects of bosentan on oxygen saturation, hemodynamics and exercise
capacity in patients with pulmonary arterial hypertension related to Eisenmenger physiology.
Patients receive bosentan or placebo for 16 weeks.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00317486
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00317486
Download to PDF